Abstract：
Systemic sclerosis (SSc) is an autoimmune disease associated to fibrotic manifestations. Interstitial lung disease (SSc-ILD), one of the main fibrotic features of SSc, is the first cause of SSc-related death. The management of SSc-ILD has recently benefited from the results of key randomised controlled trials. French authorities have approved Nintedanib for the treatment of SSc-ILD, and tocilizumab has recently been approved by the Food and Drug Administration (FDA) in the United-States (US). These recent approvals challenge the management of this fibrotic manifestation of SSc. This narrative literature review, at the crossroad of internal medicine and pulmonology, discusses what could be an up-to date approach, in terms of diagnostic and therapeutic strategies for SSc-ILD, in the light of the results from recent clinical trials.
摘要：
系统性硬化症（SSc）是一种与纤维化表现相关的自身免疫性疾病。间质性肺病（SSc-ILD），SSc的主要纤维化特征之一，是SSc相关死亡的第一个原因。SSc-ILD的管理最近受益于关键随机对照试验的结果。法国当局已批准Nintedanib用于治疗SSc-ILD，和托珠单抗最近已被美国食品和药物管理局（FDA）批准。这些最近的批准对SSc的这种纤维化表现的管理提出了挑战。这篇叙事文献综述，在内科和肺科的十字路口，讨论了什么可能是最新的方法，在SSc-ILD的诊断和治疗策略方面，根据最近临床试验的结果。
